Navigation Links
Wyeth Sets Webcast and Conference Call For 2009 Second Quarter Earnings
Date:6/10/2009

d commercialization of our products and pipeline products; government cost-containment initiatives; restrictions on third-party payments for our products; substantial competition in our industry, including from branded and generic products; emerging data on our products and pipeline products; the importance of strong performance from our principal products and our anticipated new product introductions; the highly regulated nature of our business; product liability, intellectual property and other litigation risks and environmental liabilities; the outcome of government investigations; uncertainty regarding our intellectual property rights and those of others; difficulties associated with, and regulatory compliance with respect to, manufacturing of our products; risks associated with our strategic relationships; global economic conditions; interest and currency exchange rate fluctuations and volatility in the credit and financial markets; changes in generally accepted accounting principles; trade buying patterns; the impact of legislation and regulatory compliance; risks and uncertainties associated with global operations and sales; and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 10-K, particularly the discussion under the caption "Item 1A, Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2008, which was filed with the Securities and Exchange Commission on February 27, 2009. The forward-looking statements in this press release are qualified by these risk factors. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.


'/>"/>
SOURCE Wyeth
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Wyeth Sets Webcast and Conference Call for 2007 Third Quarter Earnings
2. Wyeth Announces $5 Billion Share Repurchase Program; Declares Increase in Common Stock Dividend
3. Wyeth Pharmaceuticals Acquires Haptogen Ltd. to Boost Biotechnology Drug Discovery
4. Wyeth Announces Election of New Principal Corporate Officer
5. Wyeth Declares Preferred Stock Dividend
6. Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
7. Wyeth Provides Update on Regulatory Review of Viviant (bazedoxifene)
8. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
9. Wyeth Will Pursue Claim for Damages Resulting From Teva Pharmaceuticals Launch of Generic Pantoprazole in Violation of PROTONIX Patent
10. Wyeth Consumer Healthcare Supports U.S. Food and Drug Administration Decision for Over-the-Counter Cough and Cold Medications in Children under Two Years of Age
11. Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... YARDLEY, Pa. , March 31, 2015 /PRNewswire/ ... capabilities by integrating Mapi,s Medical Affairs and global ... Pharmacovigilance from a previously announced acquisition . ... operations are conducted by a global team ... professionals that have decades of experience in navigating ...
(Date:3/31/2015)... March 31, 2015 Today, Cryos International, ... relocation of their U.S. facilities and inventory from New ... years of experience, Cryos’ relocation is a reflection of ... move to Orlando was completed during the first weekend ... opening taking place on April 6. The new facility ...
(Date:3/30/2015)... , March 30, 2015  Multiple new research abstracts ... several important health factors. From their impact on colon ... positive effect on both gut health and vascular health, ... detail our latest understanding of walnuts, inner workings. Running ... , this annual meeting attracts an international audience ...
(Date:3/30/2015)... Md. , March 30, 2015 CASI ... dedicated to the acquisition, development and commercialization of innovative ... the global market with a commercial focus on ... Food and Drug Administration (CFDA) has approved the Company,s ... in ovarian clear cell carcinoma (OCCC) patients for its ...
Breaking Biology Technology:Mapi expands Pharmacovigilance and Risk Management capabilities 2Mapi expands Pharmacovigilance and Risk Management capabilities 3Cryos International Completes Groundbreaking Sperm Migration to Orlando, Florida 2New Findings Support the Benefits of Eating Walnuts on Overall Health 2New Findings Support the Benefits of Eating Walnuts on Overall Health 3New Findings Support the Benefits of Eating Walnuts on Overall Health 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5
... PAREXEL International,Corporation (Nasdaq: PRXL ) announced today ... Conference in Boston, MA. Josef von,Rickenbach, Chairman and Chief ... at 3:50 p.m. EDT on Thursday, September 4, 2008., ... available under the,"Upcoming Events" section on PAREXEL,s "Investors" homepage ...
... LLC, a New Jersey-based,leading provider of prescription co-pay ... has significantly expanded the scope of,the lawsuit that ... of the State,of New York, County of New ... subsidiary of McKesson Corporation. PSKW is,now seeking, in ...
... NATICK, Mass. and MUNICH, Germany, Sept. 1 ... today announced one-year data,from its landmark SYNTAX ... TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent,System to contemporary ... results demonstrated no statistically significant differences,between PCI ...
Cached Biology Technology:PAREXEL International To Present at Thomas Weisel Partners Healthcare Conference 2PSKW Expands Its Lawsuit Against McKesson to Seek Assignment of McKesson's Patent Application 2Landmark SYNTAX Trial Reports Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) Express2(TM) Stents or Bypass Surgery 2Landmark SYNTAX Trial Reports Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) Express2(TM) Stents or Bypass Surgery 3Landmark SYNTAX Trial Reports Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) Express2(TM) Stents or Bypass Surgery 4Landmark SYNTAX Trial Reports Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) Express2(TM) Stents or Bypass Surgery 5
(Date:3/23/2015)... , March 23, 2015 SoundView Technology Group issues ... (NASDAQ: NXTD ) Wocket smart wallet. SoundView was one of ... on their experience with the Wocket in multiple scenarios and ... Whole Foods and other retailers, making both debit and credit ... also says, "If the company meets their plans in ...
(Date:3/20/2015)... and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ) has announced the ... Report" report to their offering. This report ... The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... Annual estimates and forecasts are provided for the period ...
(Date:3/17/2015)... Minn. , March 17, 2015 ... technology company specializing in clinical study management systems, ... be in attendance at ARENA,s Outsourcing in Clinical ... NC.  This event provides an excellent forum for ... easy-to-use, flexible and affordable software-as-a-service (SaaS) eClinical technology ...
Breaking Biology News(10 mins):Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2
... , April 17, 2013 Vermillion, Inc. (NASDAQ: ... on gynecologic cancers and women,s health, announced the signing of ... U.S. Army Medical Research and Materiel Command (USAMRMC). ... Reduction Using OVA1 in a Treatment Algorithm for Adnexal ...
... 100% biodiesel (B100) "blend stock" samples by the U.S. ... that 95% of the samples from 2011-12 met ASTM ... guidelines for industry and are designed to ensure quality ... operation of the nation,s vehicles powered by biodiesel blends. ...
... 16, 2013 - BGI Health and ACIBADEM Healthcare ... Company Molecular Biology, signed a Memorandum of Understanding ... technologies to Turkey and improving Turkish reproductive healthcare. ... testing technologies in the areas of Monogenic disorders, ...
Cached Biology News:U.S. Army and Vermillion to Assess Health and Economic Benefits of OVA1 as a Standard of Care 2U.S. Army and Vermillion to Assess Health and Economic Benefits of OVA1 as a Standard of Care 3U.S. Army and Vermillion to Assess Health and Economic Benefits of OVA1 as a Standard of Care 4NREL survey shows dramatic improvement in B100 biodiesel quality 2BGI Health forms partnership with ACIBADEM hospital on genetic disease testing 2
Mouse monoclonal [CP23] to Ricin communis ( Abpromise for all tested applications)....
Rabbit polyclonal to Testosterone 19 ( Abpromise for all tested applications). Antigen: Testosterone 19 CME HSA (Human)...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Biology Products: